Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.

Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing. 

Paion’s novel sedation drug, remimazolam, was approved in the US, China, and Japan this year and now the European Medicines Agency is set to decide whether it should be authorized for use across the EU.

Having secured FDA approval, the UK's Acacia Pharma will market Byfavo, the first new product in the sedation space in decades, which was licensed from Italy's Cosmo and developed by Germany's Paion.